Nagel S, Schmidt M, Thiede C, Huhn D, Neubauer A
Abteilung für Innere Medizin m.S. Hämatologie und Onkologie, Virchow Klinikum, Medizinische Fakultät der Humboldt Universität zu Berlin, Germany.
Nucleic Acids Res. 1996 Oct 15;24(20):4102-3. doi: 10.1093/nar/24.20.4102.
The quantification of Bcr-Abl transcript numbers in chronic myelogenous leukemia (CML) patients described here uses simultaneous competitive PCR amplification of the target gene (Bcr-Abl) and a reference gene (porphobilinogen deaminase; Pbgd) together with a single composite competitor molecule for both targets based on heterologous sequences. Using this technique, Bcr-Abl transcript numbers could be reproducibly determined even in clinical samples known to harbour poor quality RNA.
本文所述的慢性髓性白血病(CML)患者中Bcr-Abl转录本数量的定量方法,是基于异源序列,使用针对靶基因(Bcr-Abl)和参考基因(胆色素原脱氨酶;Pbgd)的单一复合竞争分子,同时对这两个基因进行竞争性PCR扩增。使用该技术,即使在已知含有低质量RNA的临床样本中,也能可重复地测定Bcr-Abl转录本数量。